{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:19:25Z","timestamp":1790759965909,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["EQUIPE FRM EQU201903007784"],"award-info":[{"award-number":["EQUIPE FRM EQU201903007784"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"Association fran\u00e7aise contre les myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.coph.2022.102332","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:35:42Z","timestamp":1671816942000},"page":"102332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Update on anti-fibrotic pharmacotherapies in skeletal muscle disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Laura","family":"Muraine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Butler-Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Trollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Negroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102332_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102332_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ydbio.2017.07.026","article-title":"Regulation and phylogeny of skeletal muscle regeneration","volume":"433","author":"Baghdadi","year":"2018","journal-title":"Dev Biol"},{"key":"10.1016\/j.coph.2022.102332_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-019-03093-6","article-title":"Adult stem cells at work: regenerating skeletal muscle","author":"Schmidt","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coph.2022.102332_bib4","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.210110","article-title":"Fibro-adipogenic progenitors\u00a0in\u00a0skeletal muscle homeostasis, regeneration and diseases","volume":"11","author":"Molina","year":"2021","journal-title":"Open Biol"},{"key":"10.1016\/j.coph.2022.102332_bib5","series-title":"Skeletal muscle fibrosis: an overview, cell and tissue research","author":"Mahdy","year":"2018"},{"key":"10.1016\/j.coph.2022.102332_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fgene.2018.00114","article-title":"Combined therapies for duchenne muscular dystrophy to optimize treatment efficacy","volume":"9","author":"Cordova","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.coph.2022.102332_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semcdb.2016.09.013","article-title":"Fibrosis development in early-onset muscular dystrophies: mechanisms and translational implications","volume":"64","author":"Serrano","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.coph.2022.102332_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2009.01.020","article-title":"Intramuscular renin\u2013angiotensin system is activated in human muscular dystrophy","volume":"280","author":"Sun","year":"2009","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.coph.2022.102332_bib9","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.043638","article-title":"Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress","volume":"13","author":"Grounds","year":"2020","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.coph.2022.102332_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"Tgf-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.coph.2022.102332_bib11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.matbio.2018.01.014","article-title":"Regulation of fibrosis in muscular dystrophy","volume":"68\u201369","author":"Smith","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.coph.2022.102332_bib12","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1074\/jbc.274.27.18843","article-title":"The biology of the small leucine-rich proteoglycans","volume":"274","author":"Iozzo","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2022.102332_bib13","unstructured":"A. Hildebrand, W.A. Border, E. Ruoslahti, Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor, (n.d.) 8."},{"key":"10.1016\/j.coph.2022.102332_bib14","first-page":"10","article-title":"Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy","author":"Andreetta","year":"2006","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.coph.2022.102332_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/mus.20150","article-title":"Localization and early time course of TGF-?1 mRNA expression in dystrophic muscle","volume":"30","author":"Gosselin","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102332_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/mus.23858","article-title":"Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy: suramin in mdx Mouse Heart","volume":"48","author":"De Oliveira Moreira","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102332_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mus.21869","article-title":"Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-\u03b21 blocker: suramin and Antifibrosis Therapy in mdx Mice","volume":"43","author":"Taniguti","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102332_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-\u03b2 signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.coph.2022.102332_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41467-020-20289-8","article-title":"TGF\u03b2 signaling curbs cell fusion and muscle regeneration","volume":"12","author":"Girardi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102332_bib20","first-page":"68","article-title":"Targeting TGF-\u03b2 signaling for the treatment of fibrosis","author":"Gy\u00f6rfi","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.coph.2022.102332_sref21","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.3390\/ijms22137063","article-title":"Differential effects of halofuginone enantiomers on muscle fibrosis and histopathology in duchenne muscular dystrophy","volume":"22","author":"Mordechay","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.coph.2022.102332_bib22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2008.06.386","article-title":"Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone","volume":"18","author":"Turgeman","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102332_sref23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.nmd.2020.04.001","article-title":"Early pathological signs in young dysf mice are improved by halofuginone","volume":"30","author":"Barzilai-Tutsch","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102332_sref24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138634","article-title":"ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders","volume":"131","author":"Li","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2022.102332_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23819","article-title":"LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy: LTBP4 Genotype in DMD","volume":"73","author":"Flanigan","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102332_sref26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf0376","article-title":"Anti-latent TGF\u03b2 binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy","volume":"13","author":"Demonbreun","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102332_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01097-z","article-title":"\u03b1v integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis","volume":"8","author":"Murray","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102332_bib28","article-title":"Driving fibrosis in neuromuscular diseases: role and regulation of Connective tissue growth factor (CCN2\/CTGF)","volume":"11","author":"Rebolledo","year":"2021","journal-title":"Matrix Biol"},{"key":"10.1016\/j.coph.2022.102332_bib29","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1093\/hmg\/ddt352","article-title":"Reducing CTGF\/CCN2 slows down mdx muscle dystrophy and improves cell therapy","volume":"22","author":"Morales","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102332_bib30","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/jor.24337","article-title":"Blocking CCN2 reduces progression of sensorimotor declines and fibrosis in a rat model of chronic repetitive overuse","volume":"37","author":"Barbe","year":"2019","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.coph.2022.102332_bib31","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1096\/fj.202000240RR","article-title":"Blocking CTGF\/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury","volume":"34","author":"Barbe","year":"2020","journal-title":"Faseb J"},{"key":"10.1016\/j.coph.2022.102332_bib32","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/hmg\/ddy204","article-title":"The inhibition of CTGF\/CCN2 activity improves muscle and locomotor function in a murine ALS model","volume":"27","author":"Gonzalez","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102332_bib33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3233\/JND-160183","article-title":"Matrix metalloproteinases and tissue inhibitor of metalloproteinases in inflammation and fibrosis of skeletal muscles","volume":"3","author":"Alameddine","year":"2016","journal-title":"JND"},{"key":"10.1016\/j.coph.2022.102332_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2353\/ajpath.2010.091176","article-title":"Matrix metalloproteinase inhibitor Batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice","volume":"177","author":"Kumar","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2022.102332_bib35","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41467-019-10438-z","article-title":"Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B","volume":"10","author":"Hogarth","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102332_bib36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2022.102332_bib37","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cells8090984","article-title":"The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma","volume":"8","author":"Fields","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.coph.2022.102332_sref38","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119756","article-title":"An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice","volume":"281","author":"Wang","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2022.102332_bib39","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.biocel.2012.07.028","article-title":"Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells","volume":"44","author":"Morales","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.coph.2022.102332_bib40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1582-4934.2011.01354.x","article-title":"Angiotensin II receptor type 1 blockade decreases CTGF\/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles","volume":"16","author":"Cabello-Verrugio","year":"2012","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.coph.2022.102332_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1074248410381757","article-title":"Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice","volume":"16","author":"Spurney","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2022.102332_bib42","article-title":"A\u00a0randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy","volume":"5","author":"Allen","year":"2013","journal-title":"PLoS Curr"},{"key":"10.1016\/j.coph.2022.102332_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220903","article-title":"Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B","volume":"14","author":"White","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102332_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00441-013-1642-6","article-title":"Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF\/CCN-2)","volume":"353","author":"Morales","year":"2013","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.coph.2022.102332_bib45","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/hmg\/ddt514","article-title":"Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-\u03b2 signalling","volume":"23","author":"Acu\u00f1a","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102332_bib46","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1113\/EP089308","article-title":"Oral administration of angiotensin-(1\u20137) decreases muscle damage and prevents the fibrosis in rats after eccentric exercise","volume":"106","author":"Totou","year":"2021","journal-title":"Exp Physiol"},{"key":"10.1016\/j.coph.2022.102332_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2106\/JBJS.O.00545","article-title":"Angiotensin-(1-7) attenuates skeletal muscle fibrosis and stiffening in a mouse model of extremity sarcoma radiation therapy","volume":"98","author":"Willey","year":"2016","journal-title":"J\u00a0Bone Joint Surg"},{"key":"10.1016\/j.coph.2022.102332_bib48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","article-title":"Tyrosine kinase signaling in fibrotic disorders","volume":"1832","author":"Beyer","year":"2013","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.coph.2022.102332_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1414","article-title":"Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study","volume":"201","author":"Zhao","year":"2003","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.coph.2022.102332_bib50","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.coph.2022.102332_bib51","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm.3869","article-title":"Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro\/adipogenic progenitors","volume":"21","author":"Lemos","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2022.102332_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13395-018-0150-5","article-title":"Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation","volume":"8","author":"Contreras","year":"2018","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.coph.2022.102332_bib53","first-page":"4210","article-title":"Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J\u00a0Clin Orthod"},{"key":"10.1016\/j.coph.2022.102332_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0792-6","article-title":"Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy","volume":"9","author":"Pi\u00f1ol-Jurado","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coph.2022.102332_bib55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/path.4801","article-title":"PDGFR\u03b1 signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy","volume":"240","author":"Ieronimakis","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.coph.2022.102332_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119482","article-title":"In\u00a0vitro assessment of anti-fibrotic drug activity does not predict in\u00a0vivo efficacy in murine models of Duchenne muscular dystrophy","volume":"279","author":"Theret","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2022.102332_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00401-002-0635-4","article-title":"Expression of tumor necrosis factor-\u03b1 in regenerating muscle fibers in inflammatory and non-inflammatory myopathies","volume":"105","author":"Kuru","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2022.102332_bib58","first-page":"16","article-title":"Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age","volume":"30","author":"Messina","year":"2011","journal-title":"Acta Myol"},{"key":"10.1016\/j.coph.2022.102332_bib59","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nmd.2014.04.006","article-title":"Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function","volume":"24","author":"Ermolova","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102332_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90341","article-title":"Disease-modifying effects of orally bioavailable NF-\u03baB inhibitors in dystrophin-deficient muscle","volume":"1","author":"Hammers","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2022.102332_bib61","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jcph.842","article-title":"A\u00a0novel NF-\u03baB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects","volume":"57","author":"Donovan","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.coph.2022.102332_bib62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JND-210689","article-title":"A\u00a0randomized, double-blind, placebo-controlled, global phase 3 study of edasalonexent in pediatric patients with duchenne muscular dystrophy: results of the PolarisDMD trial","volume":"8","author":"Finkel","year":"2021","journal-title":"JND"},{"key":"10.1016\/j.coph.2022.102332_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JND-150113","article-title":"Current translational research and murine models for duchenne muscular dystrophy","volume":"3","author":"Rodrigues","year":"2016","journal-title":"JND"},{"key":"10.1016\/j.coph.2022.102332_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13395-017-0140-z","article-title":"Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-\/utrophin-deficient mice","volume":"7","author":"Wada","year":"2017","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.coph.2022.102332_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5016","article-title":"Targeting early PKC\u03b8-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy: targeting early T-cell infiltration ameliorates muscular dystrophy","volume":"244","author":"Lozanoska-Ochser","year":"2018","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.coph.2022.102332_bib66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2017.01.001","article-title":"Pharmacological inhibition of PKC\u03b8 counteracts muscle disease in a mouse model of duchenne muscular dystrophy","volume":"16","author":"Marrocco","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coph.2022.102332_bib67","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/hmg\/ddx173","article-title":"Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway","volume":"26","author":"Petrillo","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102332_bib68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/antiox8120581","article-title":"N-Acetylcysteine decreases fibrosis and increases force-generating capacity of mdx diaphragm","volume":"8","author":"Burns","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.coph.2022.102332_bib69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clnu.2012.06.001","article-title":"N-Acetylcysteine treatment reduces TNF-\u03b1 levels and myonecrosis in diaphragm muscle of mdx mice","volume":"32","author":"de Senzi Moraes Pinto","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1016\/j.coph.2022.102332_sref70","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101774","article-title":"Silencing COX-2 blocks PDK1\/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy","volume":"38","author":"Chen","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.coph.2022.102332_bib71","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/ATVBAHA.112.300922","article-title":"Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation","volume":"33","author":"Tanaka","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2022.102332_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.03.010","article-title":"Mechanisms of statin-associated skeletal muscle-associated symptoms","volume":"154","author":"Bouitbir","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coph.2022.102332_bib73","doi-asserted-by":"crossref","first-page":"12864","DOI":"10.1073\/pnas.1509536112","article-title":"A\u00a0new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy","volume":"112","author":"Whitehead","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102332_bib74","article-title":"Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy","volume":"7","author":"Kim","year":"2019","journal-title":"Phys Rep"},{"key":"10.1016\/j.coph.2022.102332_bib75","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3233\/JND-200524","article-title":"Simvastatin treatment does not ameliorate muscle pathophysiology in a mouse model for duchenne muscular dystrophy","volume":"8","author":"Verhaart","year":"2021","journal-title":"JND"},{"key":"10.1016\/j.coph.2022.102332_bib76","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","article-title":"Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy","volume":"82","author":"Brenman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.coph.2022.102332_bib77","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature07414","article-title":"Sarcolemma-localized nNOS is required to maintain activity after mild exercise","volume":"456","author":"Kobayashi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102332_bib78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy: Sildenafil treatment in mdx mice","volume":"228","author":"Percival","year":"2012","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.coph.2022.102332_bib79","doi-asserted-by":"crossref","first-page":"19079","DOI":"10.1073\/pnas.1013077107","article-title":"Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy","volume":"107","author":"Adamo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102332_bib80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy: Sildenafil in DBMD","volume":"76","author":"Leung","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102332_bib81","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1096\/fj.201700249R","article-title":"Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy","volume":"31","author":"Nio","year":"2017","journal-title":"Faseb J"},{"key":"10.1016\/j.coph.2022.102332_bib82","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102332_sref83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.coph.2022.102332_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor Givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol Med"},{"key":"10.1016\/j.coph.2022.102332_bib85","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lfs.2013.12.024","article-title":"The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases?","volume":"118","author":"Rodr\u00edguez-Pascual","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2022.102332_bib86","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.61.1.391","article-title":"Pathophysiology of endothelin in the cardiovascular system","volume":"61","author":"Miyauchi","year":"1999","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.coph.2022.102332_sref87","series-title":"A\u00a0negative feedback loop between fibroadipogenic progenitors and muscle fibres involving endothelin promotes human muscle fibrosis","first-page":"14","author":"Bensalah","year":"2022"},{"key":"10.1016\/j.coph.2022.102332_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.647010","article-title":"Abnormal calcium handling in duchenne muscular dystrophy: mechanisms and potential therapies","volume":"12","author":"Mareedu","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.coph.2022.102332_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-7-1","article-title":"Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice","volume":"7","author":"Swiderski","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.coph.2022.102332_bib90","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bcp.2005.05.034","article-title":"Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells","volume":"70","author":"Iwata","year":"2005","journal-title":"Biochem Pharmacol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922200159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922200159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:50:28Z","timestamp":1778615428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148922200159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":90,"alternative-id":["S147148922200159X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102332","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on anti-fibrotic pharmacotherapies in skeletal muscle disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102332"}}